Person profile

Public information reviewed

Maykin Ho

Board role

Director · BIOMARIN PHARMACEUTICAL INC (NASDAQ: BMRN)

Board role

Director · Neumora Therapeutics, Inc. (NASDAQ: NMRA)

Board role

Director · KYNTRA BIO, INC. (NASDAQ: KYNB)

Board role

Director · AGIOS PHARMACEUTICALS, INC. (NASDAQ: AGIO)

BIOMARIN PHARMACEUTICAL INC (NASDAQ: BMRN)

Director · Current mandate

Director · Executive
FollowSave PDF
More
Reports & analysisAlpha Eval
Public sources
11 reviewed
Profile ownership
Not yet claimed
Last reviewed
May 15, 2026
View sources

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
44 current organizations shown on this profile
Board positions
44 supported by public sources, 0 supplied by the profile owner
Committee roles
3Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Maykin Ho has over 30 years of healthcare and finance industry experience. She is a venture partner at Qiming Venture Partners and serves on multiple biotech company boards. She retired as a partner at Goldman Sachs in 2015 where she was a senior biotechnology analyst and co-head of healthcare for global investment research.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

Neumora Therapeutics, Inc.

2021-01-01 · current

Confirmed by public sourceView source

Director

BIOMARIN PHARMACEUTICAL INC

2021-01-01 · current

Confirmed by public sourceView source

Director

KYNTRA BIO, INC.

2018-01-01 · current

Confirmed by public sourceView source

Director

AGIOS PHARMACEUTICALS, INC.

2015-01-01 · current

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

AGIOS PHARMACEUTICALS, INC.

Open AGIOS PHARMACEUTICALS, INC. profile →

Director at AGIOS PHARMACEUTICALS, INC.

2015-01-01 → End not stated

current · source reported

Observed: 2026-09-21

AGIOS PHARMACEUTIC…AGIOS PHARMACEUTICALS, INC.BIOMARIN PHARMACEU…BIOMARIN PHARMACEUTICAL INCKYNTRA BIO, INC.KYNTRA BIO, INC.Neumora Therapeuti…Neumora Therapeutics, Inc.Maykin Ho

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingHUT DEF 14A executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Technology background.Open sourceSource 2 · Sec FilingBMRN DEF 14A director slateSupports Board role, Committee assignments, Executive company, Executive title.Open sourceSource 3 · Sec ProxyPublic profile sourceSupports Director at Neumora Therapeutics, Inc. (NASDAQ: NMRA).Open sourceSource 4 · Sec FilingKYNB DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Cybersecurity experience, Technology background.Open sourceSource 5 · Sec ProxyPublic profile sourceSupports Director at AGIOS PHARMACEUTICALS, INC. (NASDAQ: AGIO).Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:maykin-ho
Record version
public-0

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Board membership · Source reportedServes on the board of AGIOS PHARMACEUTICALS, INC.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of BIOMARIN PHARMACEUTICAL INC1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of KYNTRA BIO, INC.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of Neumora Therapeutics, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board role · CorroboratedBoard role: DirectorSupported by 2 public records2 sources
Verification
Corroborated
Confidence
92%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 7, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Committee assignments · Source reportedCommittee assignments: Audit, Compensation1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Committee assignments · Source reportedCommittee assignments: Audit, Science/Innovation1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 7, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 7, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive company · Source reportedExecutive at Aulis Capital1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 7, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 7, 2026

Executive company · Source reportedExecutive at Hut 8 Corp1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive title · Source reportedExecutive title: Executive Officer1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive title · Source reportedExecutive title: Venture Partner1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 7, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 7, 2026

Technology background · CorroboratedTechnology background: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

View all sources11 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Technology background

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 7, 2026

    Supports: Board role · Committee assignments · Executive company · Executive title

  3. https://www.sec.gov/Archives/edgar/data/1048477/000162828026026290/bmrn-20260421.htm

    Sec Proxy · Tier not stated · Reviewed May 7, 2026

    Supports: Director at BIOMARIN PHARMACEUTICAL INC (NASDAQ: BMRN)

  4. https://www.sec.gov/Archives/edgar/data/1885522/000119312526161489/nmra-20260417.htm

    Sec Proxy · Tier not stated · Reviewed Apr 24, 2026

    Supports: Director at Neumora Therapeutics, Inc. (NASDAQ: NMRA)

  5. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Cybersecurity experience · Technology background

  6. https://www.sec.gov/Archives/edgar/data/921299/000095017025058841/fgen-20250425.htm

    Sec Proxy · Tier not stated · Reviewed Apr 28, 2026

    Supports: Director at KYNTRA BIO, INC. (NASDAQ: KYNB)

  7. https://www.sec.gov/Archives/edgar/data/1439222/000119312525096719/d838751ddef14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 24, 2026

    Supports: Director at AGIOS PHARMACEUTICALS, INC. (NASDAQ: AGIO)

  8. https://www.sec.gov/Archives/edgar/data/1885522/000119312526161489/nmra-20260417.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  9. https://www.sec.gov/Archives/edgar/data/1048477/000162828026026290/bmrn-20260421.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  10. https://www.sec.gov/Archives/edgar/data/921299/000095017025058841/fgen-20250425.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  11. https://www.sec.gov/Archives/edgar/data/1439222/000119312525096719/d838751ddef14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership